Philip Kluin

Search results

• 2013

  Visibility Of Bone Lesions In Relapsed Multiple Myeloma Can Be Improved By FDG-PET Scanning

  De Waal, E. G. M., Slart, R. H. J. A., Leene, M. J., Kluin, P. & Vellenga, E., 15-Nov-2013, In: Blood. 122, 21, 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2007

  Treatment of MALT lymphoma in Sjogren's syndrome: a retrospective clinical study and a proposal for treatment guidelines

  Pijpe, J., Bootsma, H., Vissink, A., Spijkervet, F. K. L., Roodenburg, J. L. N., Kluin, P. M., Kallenberg, C. G. M. & van Imhoff, G. W., May-2007, In: Oral Oncology. p. 214-214 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2004

  Decrease of activity in Sjogren's syndrome after treatment with rituximab for associated malt-lymphoma

  Pijpe, J., Van Imhoff, G., Kluin, P., Spijkervet, F., Roodenburg, J., Vissink, A., Kallenberg, C. & Bootsma, H., Jul-2004, In: Annals of the Rheumatic Diseases. 63, p. 354-354 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

  100 Citations (Scopus)

• Rituximab (anti-CD20) for the treatment of primary Sjogren's syndrome.

  Pijpe, J., Bootsma, H., Van Imhoff, G., Vissink, A., Mansour, K., Van der Wal, J., Roozendaal, C., Kluin, P., Spijkervet, F., Roodenburg, J. & Kallenberg, C., Sept-2004, In: ARTHRITIS AND RHEUMATISM. 50, 9, p. S575-S575 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic